0562/SAH/1112/SAH Dr Max Dias Update on prostate cancer and BPH Robotic, Laparoscopic and General Urological Surgeon.

Slides:



Advertisements
Similar presentations
Prostate Cancer What a GP Needs to Know
Advertisements

Prostate Cancer Foundation of Australia Ambassador Presentation Prostate Health 2007.
Clinically localized prostate cancer: Prostatectomy David D. Thiel, MD Mayo Clinic Florida Department of Urology.
Oncology and Palliative Care: Promoting the Comfort and Cure Model Parag Bharadwaj, MD FAAHPM.
Screening for Prostate Cancer: Sharing the Decision 7/1/03.
What is the evidence of benefits of PSA screening for prostate cancer? Outpatient Medicine.
Benign Prostatic Hyperplasia Dr.Bandar Al Hubaishy Urology Department KAUH.
Prevention Strategies Rajesh G. Laungani MD Director, Robotic Urology Chairman, Prostate Cancer Center Saint Joseph’s Hospital, Atlanta.
Otis W. Brawley, M.D. Chief Medical and Scientific Officer Executive Vice President American Cancer Society Professor of Hematology, Medical Oncology,
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
EVIDENCE AND DEBATE SCREENING FOR PROSTATE CANCER.
PSA & Prostate Cancer Dan Burke Consultant Urological Surgeon
Prostates & Pissing in the Wind. The Laytons Bob December 25, 1925 – May 9, 2002 Jack July 18, 1950 – August 22, 2011.
Prostate Cancer: Education & Outreach Center for Cancer Prevention & Control Prevention and Health Promotion Administration Maryland Department of Health.
PROGRESS IN MANAGEMENT OF PROSTATE CANCER Presented by Dr. J. Nkusi on the October 2007, 38 th Congress of the Botswana Medical Association.
Prostate Cancer: Education & Outreach
Prostate Cancer Screening 2012 Paul L. Crispen, MD Department of Surgery University of Kentucky.
Prostate Cancer Screening Assistant Professor Charles Chabert Men’s health Seminar Ballina April 2011 prostates.com.au.
Mr Jim Adshead MA MD FRCS (Urol) Consultant Urological Surgeon Lister Hospital, Stevenage Spire Hospital Harpenden E mail:
“Fighting Cancer: It’s All We Do.” ™. Restoring Quality of Life And Managing Side Effects Ulka Vaishampayan M.D. Chair, GU Multidisciplinary team Associate.
Finding N.E.M.O. Marvin R. Balaan, MD, FCCP System Division Director, Division of Pulmonary and Critical Care Medicine Allegheny Health Network, Pittsburgh.
Prostate Cancer James B. Benton,M.D.. Prostate Cancer Significant of the clinical problem Early detection/screening Prevention/Management.
A/Prof Brian Cox Cancer Epidemiologist Dunedin. Research Associate Professor Brian Cox Hugh Adam Cancer Epidemiology Unit Department of Preventive and.
LUTS Shawket Alkhayal Consultant Urological Surgeon Benenden Hospital Tunbridge Wells Nuffield Hospital.
Urology Update Sanofi- Aventis
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
A GENERAL OVERVIEW OF PROSTATE CANCER. PROSTATE CANCER 101 SPONSORED BY THE CALIFORNIA STATE PROSTATE CANCER COALITION AND THE NATIONAL ALLIANCE OF STATE.
Sandeep Bagla, MD Cardiovascular & Interventional Radiology Inova Alexandria Hospital.
Figure 1. Gross specimen of prostate gland.. Figure 2. Microscopic effects of BPH.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Prostate Cancer Screening Risk Management Ben Inch.
Prostate Screening in the New Millennium Dr Pamela Ajayi MD PathCare.
The GOLIATH Study ..
Understanding Prostate Myths
Prostate Cancer Screening Who needs it?... and who doesn’t. Presented by: Michael K. Yu, MD.
Life after Prostate Cancer and its treatment Mr Sanjeev Pathak Consultant Urological Surgeon and Cancer Lead Doncaster and Bassetlaw NHS Trust 12 th March.
Prostatectomy operations in England South West Public Health Observatory Trends in the use of radical prostatectomy in England Sean McPhail.
Men’s health. Mr Williams Mr Williams is 56, African-Caribbean and comes to see you with a 6month history of increasing difficulty passing urine and nocturia.
Prostate cancer update Suresh GANTA Consultant urological surgeon Manor Hospital.
Manit Arya Consultant Urological Surgeon UCLH and PAH Transforming the Pathway in Prostate Cancer.
Benign Prostatic Hyperplasia Rajan Narula Senior Staff Specialist The Townsville Hospital.
Prostate cancer and socio-economic deprivation When PCTs are ranked according to their income score using the Indices of Multiple Deprivation (IMD)* there.
Screening for Prostate Cancer
Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia: Trends in Medical Management
PSA, PCA-3 and peace of mind in suspected prostate cancer
DESIGN AND APPROVAL OF A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED TRIAL OF THE ACE INHIBITOR CAPTOPRIL IN COMBINATION WITH IBUPROFEN IN THE TREATMENT.
Group Issues Guidelines on Prostate Cancer Screening . . .
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Benign prostatic hyperplasia
2017 USPSTF Draft Recommendations for Prostate Cancer Screening
Dr. John Jordan Dr. Stephen Pautler
CONVERSATIONS ON PROSTATE CANCER
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Willie Underwood, III, MD, MS,MPH
Evaluation and Medical Management of Benign Prostatic Hyperplasia
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Prostate Cancer Screening- Update
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
P8-2 Rezum water vapour thermal therapy for benign prostatic hyperplasia: early results from the United Kingdom Max Johnston1, Tina Gehring1, James Montgomery1,
Lung Cancer Screening Sandra Starnes, MD Professor of Surgery
Active Surveillance for Low Risk Prostate Cancer
Prostate Cancer Update
A decade after the Surgical Treatment for Ischemic Heart Failure (STICH) trial: Weaving firm clinical recommendations from lessons learned  Robert E.
How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia?  Vincenzo Mirone 
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
HERBERT C. RUCKLE, M. D. , GEORGE G. KLEE, M. D. , PH. D. ,, JOSEPH E
Michael Marberger  European Urology Supplements 
Maintaining bone health while on ADT for Prostate Cancer
Prostate cancer screening beyond PSA – STHLM3 and/or MRI
Presentation transcript:

0562/SAH/1112/SAH Dr Max Dias Update on prostate cancer and BPH Robotic, Laparoscopic and General Urological Surgeon

Prostate cancer Is prostate cancer a disease worth diagnosing?

Prostate cancer Hell Yeah!

Cancer Mortality in NSW

Metastatic cancer

Side effects of androgen deprivation Decreased cognitive function Muscle weakness and increased fat Hot flushes Increased cardiovascular morbidity and death Osteoporosis with fracture Impaired glucose metabolism Decreased libido and impotence

PSA Screening studies PLCO – Poor study protocol – 45% entered the trial with a history of screening – Many in control arm continued to be screened – 90% in the control arm had PSA testing ERSPC – PSA naïve patients – 21% reduction in mortality Reevaluating PSA Testing Rates in the PLCO Trial. Shoag et al. N Engl J Med 2016; 374: May 5, 2016May 5, 2016

Prostate vs Breast Ca screening Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics H. Gilbert Welch, M.D., M.P.H., David H. Gorski, M.D., Ph.D., and Peter C. Albertsen, M.D. N Engl J Med 2015; 373: October 29, 2015October 29, 2015

NHMRC guidelines

Age considerations

Shared decision making “In my experience, fear comes from not knowing what to expect and not feeling you have any control over what’s about to happen. When you feel helpless, you’re far more afraid than you would be if you knew the facts.” ― Chris Hadfield, An Astronaut's Guide to Life on EarthChris Hadfield, An Astronaut's Guide to Life on Earth

Shared decision making Tell me and I’ll forget. Show me and I may not remember. Involve me and I’ll understand. - Native American Proverb

Gallium 68-PSMA – PET Scan Prostate specific membrane antigen

Gallium 68-PSMA – PET Scan EUROPEAN UROLOGY 64 (2013) 862–864

PSMA – PET Scan

Focal therapy Focal Therapy in Prostate Cancer: International Multidisciplinary Consensus on Trial Design Peter T. Scardino European Urology, Volume 65 Issue 6, June 2014, Pages Peter T. ScardinoVolume 65 Issue 6, June 2014, Pages

Focal therapy HIFU Cryotherapy Radiofrequency ablation (RFA) Focal brachytherapy Focal Electroporation Focal laser therapy

HIFU

Focal therapy Theory: treat part of prostate and minimize side effects. Long term data not available Prostate cancer is a multifocal disease Predominantly used in low risk disease We already have an alternative for low risk disease- active surveillance

BPH

BPH and risk of PCa and Bladder Ca Meta-analysis of observational studies – PCa 4x higher in men with BPH – Bladder Ca 2.5x in men with BPH – Asian men with BPH had 6x PCa risk Benign Prostatic Hyperplasia and the Risk of Prostate Cancer and Bladder Cancer: A Meta- Analysis of Observational Studies. Medicine (Baltimore) May;95(18) Dai X1, Fang X, Ma Y, Xianyu J.

BPH Alpha blockers – Prazosin, Flomaxtra, Alfuzosin 5 alpha reductase inhibitors – Dutasteride, Finasteride Combined – Duodart – (Anticholinergics, Mirabegron) – Cialis 5mg Surgical treatments – TURP, Laser, Microwave, TUNA, Urolift

Urolift

Patient selection – Prostate volume <80cc – Patient who cannot tolerate medications or who does not want side effects of medication – Patients not suitable for or not wanting surgery

Urolift procedure

Urolift BPH-6 and LIFT study presented at this year’s EAU – Data out to 4 years – Preservation of sexual benefits – Significantly better urine flow and IPPS with TURP

Prostate artery embolization (PAE) Limitations – Technically challenging – Unilateral embolization associated with 50% clinical success – Ionizing radiation – Potential for severe complications with non-target embolization – Revascularization and regrowth

Prostatic artery embolization The National Institute for Health Care Excellence (NICE) in the UK published a procedure guidance of PAE for BPH – recommend that the procedure should only be performed in the context of research and that consideration of the patient should be undertaken by a multidisciplinary team (including an interventional radiologist and urologist).

Take home messages Prostate cancer is the second leading cause of cancer disease- It is important! Early detection and cure is the only way to reduce mortality and morbidity Continue performing DRE if comfortable Screen for prostate cancer in those with BPH Urolift and PAE are novel treatments with limited application and deserve further investigation